Endocrine and Metabolic Flashcards
Cushing’s syndrome
- aetiology: define, pathophysiology, risk factors
- clinical features
- investigations
- management
- prognosis + complication
Syndrome associated with chronic inappropriate elevations of free circulating cortisol
ACTH dependent
- Excess ACTH from pituitary adenoma (Cushing’s disease)
- Ectopic ACTH (small cell lung cancer)
ACTH independent
- Adrenal adenoma
- Adrenal carcinoma
Mostly females 20-40yrs old
RF
- Exogenous corticosteroid use (most common cause overall)
- Pituitary or adrenal adenoma
- Adrenal carcinoma
excess alcohol consumption can mimic cushings
CLINICAL FEATURES
- Thin, easily bruisable skin with ecchymoses
- Stretch marks (striae)
- Proximal myopathy (muscle weakness)
- Central adiposity
- Fatigue
- Hirsutism
- Acne
- Hyperpigmentation (if ACTH dependent)
- Lethargy & depression
- Osteopenia & osteoporosis
- Hypertension
- Hyperglycaemia
- Increased susceptibility to infection
KEY FEATURES
- Bruising and thin skin
- Myopathy
- Purple striae >1cm wide
- DM, HTN, osteoporosis at young age
INVESTIGATIONS
1st Low dose (1mg) overnight dexamethasone suppression test
- Morning cortisol >50 nanomol/L
- Patient is given 1 mg of dexamethasone at 11 pm and a plasma cortisol level is measured the following morning at 8am
- Patients with Cushing’s syndrome do not have their morning cortisol spike suppressed, will still be raised
High dose dexamethasone suppression test: to disinguish between cushings disease and ectopic ACTH production.
Excess ACTH production from pituitary is inhibited by high dexamethasone dose however autonomous cortisol production from adrenals won’t be inhibited
so if Cushings Disease then ACTH will be supressed, if its is an ectopic ACTH then it wont be supressed
24 hour urinary free cortisol or late night salivary cortisol: elevated in cushings
Other:
Pregnancy Test
Bloods:
- hyperglycaemia (cushings leads to glucose intolerance and diabetes)
- hypokalaemia : usually K+ is very low in Ectopic ACTH production due to small cell lung cancer
- hypernatraemia
- metabolic alkalosis (due to increased H+ excretion and bicarbonate reabsorption)
MANAGEMENT
Drug induced Cushings: stop steroids or lower dose
Metyrapone or ketoconazole (inhibits cortisol synthesis)
osilodrostat, ketoconazole, levoketoconazole, metyrapone (pituitary or adrenal)
- Transsphenoidal pituitary adenomectomy (if pituitary tumour)
IF HAD TPA MUST BE ON HYDROCORTISONE X3 - Adrenalectomy (if adrenal adenoma or carcinoma)
IF HAD ADRENALECTOMY must be on: hydrocortisone x3 per day and fludrocortisone X1
PROGNOSIS
Untreated disease has a poor survival rate of 50% at 5 years. Patients may have decreased quality of life after treatment
COMPLICATIONS
- diabetes
- osteoporosis
- hypertension
- pre-disposition to infections
Addisons Disease
- aetiology: define, pathophysiology, risk factors
- clinical features
- investigations
- management
- prognosis + complication
Primary adrenal insufficiency → decreased production of adrenocortical hormones (reduced cortisol and aldosterone)
Main causes:
- Autoimmune (more developed countries)
- Tuberculosis (more common worldwide)
- May be caused by metastases
Other causes:
- Meningococcal septicaemia (Waterhouse-Friderichsen syndrome)
- HIV
- Antiphospholipid syndrome
Risk Factors:
- Female
- Presence of adrenocortical autoantibodies
- Adrenal haemorrhage
- Anticoagulant use
Addisonian crisis: A sudden worsening of symptoms and drop in cortisol levels
- Sudden withdrawal of steroids if patient on long-term steroid medication
- sepsis
- surgery
CLINICAL FEATURES
- Fatigue
- Abdominal pain
- Weight loss
- Hyperpigmentation: -ve feedback causes increased ACTH leading to increased POMC, leading to increased α-MSH
- Nausea and vomiting
- Hypotension
- Hypoglycaemia → may cause dizziness and falls
Addisonian Crisis: Severe hypovolaemia and hyponatraemia
INVESTIGATIONS
ACTH stimulation test (short synacthen test): synacthen should stimulate adrenal glands to secrete cortisol but will not happen in Addisons
Morning serum cortisol: do if first test is unavailable aka in GP. Take blood between 8-9am when cortisol peaks, if its low suspect addisons
Plasma ACTH (take at same time)
Bloods:
- seum electrolytes : check for hyponatraemia and hyperkalaemia (caused for aldosterone deficiency)
- ABG: metabolic acidosis with normal anion gap
- FBC: anaemia
- Glucose- hypoglycaemia
MANAGEMENT
Hydrocortisone given in 2 or 3 divided doses (glucocorticoid) + fludrocortisone (mineralocorticoid)
If patient is having an illness: hydrocortisone dose should be doubled but fludrocortisone stays same
Addisonian crisis:
- IV hydrocortisone sodium succinate
- Fluid resus- saline (saline with 5% dextrose is good to ensure dont worsen low sodium by doing too much with glucose dose)
- Glucose (if hypoglycaemia)
Phaemochromocytoma (NOT NEEDED)
- aetiology: define, pathophysiology, risk factors
- clinical features
- investigations
- management
- prognosis + complication
Tumour of adrenal medulla- irregular secretion of adrenaline and noradrenline
- hypertension (around 90% of cases, may be sustained)
- headaches
- palpitations
- sweating
- anxiety
24 hour urinary collection of metanephrines
Surgery but need medical management before
- Alpha blocker e.g. phenoxybenzamine
- Beta blocker e.g. propranolol
Alpha blocker before beta
Primary Hyperaldosteronism (NOT NEEDED)
- aetiology: define, pathophysiology, risk factors
- clinical features
- investigations
- management
- prognosis + complication
- hypertension
- hypokalaemia → muscle weakness
- metabolic alkalosis
- Bilateral idiopathic adrenal hyperplasia- most common
- Adrenal adenoma (Conn’s syndrome)- 2nd most common
- Unilateral hyperplasia
- Familial hyperaldosteronism
- Adrenal carcinoma
1st Plasma aldosterone/renin ratio → high in this disease
High res CT abdo to differentiate between unilateral adenoma and bilateral hyperplasia
- If CT normal- Adrenal venous sampling (AVS) to distinguish between them
If renin is higher aka low aldosterone/renin ratio- Think renal artery stenosis
MANAGEMENT
adrenal adenoma: laparoscopic adrenalectomy
bilateral adrenocortical hyperplasia: aldosterone antagonist- spirinolactone
Diabetes Insipidus
- aetiology: define, pathophysiology, risk factors
- clinical features
- investigations
- management
- prognosis + complication
Condition in which kidneys are unable to concentrate urine due to inadequate secretion or sensitivity to ADH, resulting in the production of large quantities of dilute urine
ADH increases water reabsorption into blood in collecting duct via V2 receptors- so lack of sensitivity or low secretion results in lots of peeing
Two types:
1) Central/cranial: INSUFFICIENT/deficiency levels of ADH from posterior pituitary
- pituitary tumour/surgery
- traumatic brain injury
- infection (meningitis)
- sarcoidosis
- TB
- SAH
- hereditary haemochromatosis
2) Nephrogenic: resistance as defective ADH receptors in the distal tubules and collecting ducts
- lithium therapy
- inherited (AVP2 gene)
- electrolyte imbalances (hypercalcaemia or hypokalaemia)
- idiopathic
CLINICAL FEATURES
- Polyuria → with very dilute urine
- Nocturia → restless sleep, daytime sleepiness
- Polydipsia → excessive thirst
- Dehydration:
- tachycardia
- reduced tissue turgor
- dry mucous membranes
INVESTIGATIONS
Urine osmolality:
- Low urine osmolality
- High serum osmolality
To confirm do water deprivation test:
- if osmolality corrects itself: psychogenic polydipsia
- if osmolality doesnt correct itself: After 8 hours administer desmopressin
- Urine osmolality will rise in CDI
- Urine osmolality will remain low in NDI
Hypertonic saline stim test with copeptin measurement
baseline copeptin level >21.4 picomol/L is diagnostic of nephrogenic DI; after given hypertonic saline copeptin level >4.9 picomol/L differentiates central DI from primary polydipsia
MRI to look for brain/pituitary tumour
Urine Dip- exclude diaetes mellitus as a cause of polyuria
24 hour urine collection
Bloods:
Hypernatraemia: if sodium is low then psychogenic polydipsia
Hypokalaemia: on ECG will show as T wave inversion,QT prolongation, U waves. Associated with nephrogenic
Hypercalcaemia: nephrogenic
Normal blood glucose
TREATMENT
Hypernatramia correction: Oral of IV fluids to prevent dehydration. If correct too fast the predisposes to cerebral oedema
Central DI: Intranasal desmopressin
Nephrogenic DI: Discontinue cause if its a medication like lithium, thiazide diuretics (hydrochlorothiazide), sodium restriction
COMPLICATIONS
- hypernatraemia
- iatrogenic hyponatraemia (side effect of desmopressin)
What drug should not be given with thiazide diuretics and what symptoms occur
Digoxin
arrythmias, N+V, lethargy, anorexia, yellow-green vision, confusion, generally unwell
Diabetes Mellitus type 1
- aetiology: define, pathophysiology, risk factors
- clinical features
- investigations
- management
- prognosis + complication
autoimmune response that triggers the destruction of insulin-producing beta cells in the pancreas leading to an absolute insulin deficiency (⇒ lipolysis and ketogenesis)
Usually in childhood, associated with HLA DR3/4 gene and see autoimmune diseases in FHx
CLINICAL FEATURES
- Polyuria
- Polydipsia
- Unexplained weight loss
- Fatigue
- Increased susceptibility to infection
- blurred vision, N&V, abdo pain, dehydrated, tachy
May get gastroparesis : bloating, voiting and erratic blood glucose control due to neuropathy of the vagus nerve
FEATURES SPECIFIC TO TYPE 1
DKA is 1st manifestation in 1/3 of cases
- Nausea and vomiting
- Abdo pain
- Kussmaul breathing → deep, rapid breathing
- Sweet smelling breath
INVESTIGATIONS:
Blood glucose: Fasting plasma glucose, random non-fasting plasma glucose, HbA1c, 2 hour OGTT
1) Finger prick
2) one-off blood glucose (fasting or non-fasting)
In diabetic this is 11.1mmol/L or over
If fasting:
Normal: below 5.5, prediabetes/impaired 5.6-6.9, diabetic 7 or over
3) HbA1c (average blood glucose over last 2-3 months)
Normal: Below 42 mmol/mol (Below 6.0%)
Prediabetes: 42 to 47 mmol/mol (6.0% to 6.4%)
Diabetes: 48 mmol/mol or over (6.5% or over)
- Sickle cell, G6PD deficiency, hereditary spherocytosis can all cause lower than expected because of reduced RBC lifespan.
4) 2 hour OGTT Oral glucose tolerance test: 75g glucose and measure after 2 hours
Normal= below 7.8, impared glucose tolerance/prediabetes is 7.8 to 11 (if also had impaired fasting glucose), diabetes is over 11
Diagnostic for symptomatic patients: Fasting glucose ≥7 mmol/L OR random glucose ≥11.1 mmol/L
Diagnostic for asymptomatic= same but repeat on two different days
C Peptide: decreased in Type 1
Urine Dip: Glucosuria, Ketone bodies (secific to type 1), Microalbuminuria (signs of nephropathy)
Anti-GAD antibodies, Islet cell antibodies (IA2 and IA2-beta), and the zinc transporter ZnT8. (specific to type 1)
MANAGEMENT
Basal-bolus insulin which is a combo of:
- Long acting (e.g. insulin glargine, detemir, degludec subcutaneous injection OD)
- Short acting (e.g. insulin lispro or aspart, glulisine before meals)
Usually when first diagnosed: basal bolus using insulin detemir twice daily, bolus using any of the short acting
Consider Metformin in patients with BMI over 25
COMPLICATIONS
- Microvascular
- Retinopathy
- Neuropathy (foot ulcers)
- Nephropathy
- Macrovascular
- MI/stroke/PVD
- Metabolic
- DKA
- HHS
- Hypoglycaemia
- eating disorders and depression
COMPLICATIONS OF TYPE 1
- DKA
- hypoglycaemia
- retinopathy
- diabetic kidney disease
- neuropathy (peripheral or autonomic)
- CVD
Diabetes Mellitus type 2
- aetiology: define, pathophysiology, risk factors
- clinical features
- investigations
- management
- prognosis + complication
insulin resistance (decreased insulin sensitivity) and relative insulin deficiency (insulin production reduces over time)
Strong genetic component and association with obesity and a sedentary lifestyle
RF:
- Obesity
- Hypertension
- South Asian/Afro-Caribbean ethnicity
- Old age
- FHx
- Dyslipidaemia
- CVD
- Polycystic ovary syndrome
MODY (maturity onset diabetes of the young). MODY limits the body’s ability to produce insulin, is Autosomal dominant inheritance, usually a FHx of early onset diabetes.
Treatment for HNF1A MODY: Sulfonylureas e.g. gliclazide
CLINICAL FEATURES
- Polyuria
- Polydipsia
- Unexplained weight loss
- Fatigue
- Increased susceptibility to infection
May get gastroparesis : bloating, voiting and erratic blood glucose control due to neuropathy of the vagus nerve
FEATURES SPECIFIC TO TYPE2
- Many patients are asymptomatic
- Some may present with HHS (hyperosmolar hyperglycaemic state)- blood glucose very high >40mmol and severe dehydration and confusion
- Acanthosis nigricans (hyperpigmentation)
- UTI, candidal infection, skin infections, fatigue, blurred vision
INVESTIGATIONS:
Blood glucose: Fasting plasma glucose, random non-fasting plasma glucose, HbA1c, 2 hour OGTT
Finger prick
one-off blood glucose (fasting or non-fasting)
In diabetic this is 11.1mmol/L or over
If fasting:
Normal: below 5.5, prediabetes/impaired 5.6-6.9, diabetic 7 or over
HbA1c (average blood glucose over last 2-3 months)
Normal: Below 42 mmol/mol (Below 6.0%)
Prediabetes: 42 to 47 mmol/mol (6.0% to 6.4%)
Diabetes: 48 mmol/mol or over (6.5% or over)
- Sickle cell, G6PD deficiency, hereditary spherocytosis can all cause lower than expected because of reduced RBC lifespan.
Oral glucose tolerance test: 75g glucose and measure after 2 hours
Normal= below 7.8, impared glucose tolerance/prediabetes is 7.8 to 11 (if also had impaired fasting glucose), diabetes is over 11
Diagnostic for symptomatic patients: Fasting glucose ≥7 mmol/L OR random glucose ≥11.1 mmol/L
Diagnostic for asymptomatic= same but repeat on two different days
C Peptide: increased in Type 2
Urine Dip: Glucosuria, NO Ketone bodies, Microalbuminuria (signs of nephropathy)
TREATMENT
Lifestyle: diet, exercise, education with a HbA1c target
TARGETS: 48mmol/L if managed with lifestyle or one diabetic drug (step 1)
53mmol/L if on two or more diabeteic drugs or on a drug that can cause hypoglucaemia like sulfonylureas
Consider : BP, lipids, antiplatelets, add on therapies if have CKD
If QRISK over 10% also start atorvastatin 20mg oral, if have CVD/IHD/PAD then 80mg
If QRISK (for CVD) changed at any time to over 10% then add SGLT2 inhibitor
If have CVD/IHD/PAD also give antiplatelet- aspirin 75mg
BP management
- Step 1: ACEi or ARB (ARB preferred for black African patients)
- Step 2: Add CCB e.g. amlodipine or thiazide-like diuretic (TLD) e.g. indapamide
- Step 3: ACEi + CCB + TLD
- Step 4: Check K+ and if it’s <4.5 add spironolactone and if >4.5 add beta blocker
CKD- give ACEi, if already taking ACEi give SGLT2 + angiotensin 2 receptor antagonist, if already taking. If CKD stage 3/4 then finerenone
Glycaemic control:
Step 1: Metrofmin if HbA1c still over 48 despite lifestyle advice. If their eGFR is under 30 may cause accumulation due to renal impairment so can get lactic acidosis.
If high risk of CVD, established CVD or CHF then add SGLT-2
If metformin isnt tolerated due to GI issues try modified release before second line
If metformin contraindicated then move onto second line
Step 2 if HbA1c or not tolerating metformin add another drug:
- DPP4i’s (gliptins)
- Sulfonylureas (gliclazide + glimepiride)
- SGLT-2i’s (flozins)- use if CVD/heart failure risk
- Pioglitazone
Step 3: add another drug or try basal insulin, will need a Glucagon kit for treating hypoglycaemias
If triple therapy not effective switch one of the drugs for a GLP-1 mimetic if BMI over 35 or insulin would impact work
If admitted to hospital for ACS: stop meds and start IV dose adjusted insulin infusion with glucose monitoring
COMPLICATIONS
- diabetic kidney disease
- impaired vision
- amputation
- stroke
- infection
- CHF
- Obstructive Sleep apnoea
Drugs used in Diabetes, mode of action, side effect and what patients theyre contraindicated in
Metformin: increases insulin sensitivity and reduces hepatic gluconeogenesis.
SE: GI issues- Nausea or diarrhoea, weight NEUTRAL, lactic acidosis (therefore if have vomiting or diarrhoea, dehydrated, sepsis, CT with contrast, renal or heart failure, if the patient is frail or elderly must STOP
Sulfonylureas (gliclazide): stimulating the release of insulin from beta cells pancreas (act on ATP sensitive K+ channels). best 2nd choice in non obese
SE: if too much insulin secreted = hypoglycaemia, weight gain.
Dont give to severe renal impairment (CKD)
Overdose= hyperinsulinamia and hgigh C-peptide
dont give on morning of surgery because hypo
SGLT-2 inhibitors (flozins): inhibits SGLT co transporter 2 in the renal proximal convoluted tubule to reduce glucose reabsorption and increase urinary glucose excretion. Best 2nd for obese patients.
Add SGLT-2 if CVD, high risk of CVD, CHF
SE: weight loss, UTIs, fournier’s gangrene, DKA if used with insulin.
Contraindicated if active foot disease (skin ulceration)
DPP4 inhibitors (gliptins): reduce peripheral breakdown of incretins like GLP-1
SE: weight neutral (may increase satiety so useful in obese patients)
Pioglitazone
Weight gain, Fluid retention (dont give in HF), liver dysfunction, fractures
dont give in bladder cancer
GLP1 agonist (exantide): increase insulin secretion and inhibit glucagon secretion
SE: weight loss
can continue GLP1 and DPP4 on the day of surgery
Diabetes Ketoacidosis
- aetiology: define, pathophysiology, risk factors
- clinical features
- investigations
- management
- prognosis + complication
Acute metabolic complication of diabetes that is potentially fatal and requires prompt medical attention
ONLY TYPE 1 as no insulin to suppress lipolysis leading to ketone formation and acidosis. May be the first presentation of T1DM
RF: infection (increases cortisol which is an antagonist of insulin so body needs more insulin), inadequate insulin therapy (non-compliance), undiagnosed T1DM, MI
T1DM SICK DAY RULE: continue normal insulin dose, check blood glucose more regularly, 3L of fluid over 24 hours, self monitor ketones regularly throughout the day
CLINICAL FEATURES
- Diabetic symptoms: Increased thirst (polydipsia), Polyuria, Weight loss, Tiredness
- Nausea and vomiting
- Severe abdo pain
- Dehydration
- Dry mucous membranes
- Decreased skin turgor
- Slow CRT (cap refill)
- Tachycardic
- Hypotensive
- Hyperventilation/ Kussmal breathing: Decrease in pH stimulates resp centre to try and correct acidosis by blowing off CO2
- Reduced consciousness
- Fruity breath
- Rapid onset- less than 24 hours
INVESTIGATIONS
Venous Blood gas: metabolic acidosis with raised anion gap, partial resp compensation by hyperventilating
Blood ketones: raised
Blood glucose: raised
U+E: low sodium, high potassium as no insulin
FBC- leukocytosis
Alcoholic ketoacidosis: normal or low glucose : give rehydration with IV saline and thiamine to prevent wernickes
MANAGEMENT
Rehydration : IV fluids (isotonic saline 10ml/kg, + potassium chloride repletion IF potassium low)
- Cerebral Oedema can happen if rehydrated too quickly, will get headaches, reduced consciousness, rise in BP, seizures
Reduce Ketones: fixed rate IV insulin 0.1 unit/kg/hr, do after fluids
- if glucose falls below 14mmol/lthen 10% dextrose
- continue long acting insulin but stop short acting insulin
If severe metabolic acidosis: IV bicarbonate
Signs that DKA has not resolved in 24 hours: ph under 7.3 (acidosis), ketones over 0.6mmol/L or 2+ on urine dip, bicarbonate lower than 15
- refer to senior endocrinologist
PROGNOSIS
close monitoring and correction of electrolytes leads to reduction in overall mortality
COMPLICATIONS
hypokalaemia and hypoglycaemia from excessive insulin therapy
Hypophosphataemia : continue with insulin therapy and give IV phosphate replacement therapy
Cerebral Oedema
Cardiac Arrythmias
Diabetic Eye Disease/ Retinopathy
- aetiology: define, pathophysiology, risk factors
- clinical features
- investigations
- management
- prognosis + complication
Two types:
- Non-proliferative (early stage, less severe)
- Proliferative (more advanced)
- Eventually occurs in some degree in all patients with DM
- Most common cause of visual impairment and blindness in patients aged 25-74
Progression:
Background retinopathy → pre-proliferative retinopathy → proliferative retinopathy (maculopathy)
CLINICAL FEATURES
- Asymptomatic until v late stages
- Visual impairment- progression to blindness
- Maculopathy- changes to macula
- Non-proliferative features
- Microaneurysms
- Blot haemorrhages
- Cotton wool spots
- Hard exudates
- Proliferative features
- Non-proliferative features usually present
- Retinal neovascularisation (lots of blood vessels in macula)
- Retinal detachment (see a yellow line)
- Vitreous Haemorrhage (thick haemorrhage)
Retinal detatchment causes sudden painless complete vision loss, starts peripherally and progresses centrally. Get flashers/floaters too
Vitreous haemorrhage : another cause of complete vision loss
- Bleeding into vitreous humour
- Sudden appearance of spots/floaters- blurred vision
- No flashing lights like in retinal detachment
INVESTIGATIONS
Fundoscopy:
Background retinopathy: microaneurysms, blot haemorrhages, hard exudates
Pre-proliferative: background and cotton wool spots
Proliferative: non-proliferative + neovascularisation (vessels on disk)
Maculopathy: hard exudates near macula (centre of the picture (the bright thing is optic disk))
Optical coherence tomography
MANAGEMENT
For all diabetics:
- Improve blood glucose
- Improve BP control
- Improve serum lipid control
- Regular review by ophthalmology
Background retinopathy: improve glycaemic control and observe regularly
Pre-proliferative: Pan-retinal laser photocoagulation
proliferative: Pan-retinal laser photocoagulation and intravitreal VEGF inhibitors
Maculopathy: VEGF inhibitors
PROGNOSIS
chronic, progressive disease. Visual loss may develop despite treatment
COMPLICATIONS
- Cataract
- Macular oedema
- Visual field loss
Diabetes Nephropathy
- aetiology: define, pathophysiology, risk factors
- clinical features
- investigations
- management
- prognosis + complication
patient with long-standing diabetes (>10 years) with albuminuria and/or reduced estimated glomerular filtration rate (eGFR)
CKD most common cause
20-40% of patients with diabetes mellitus develop
Pathological changes:
- Mesangial expansion
- Glomerular basement membrane thickening
- Glomerulosclerosis
CLINICAL FEATURES
- Hypertension
- Oedema in advancing diabetic nephropathy
- Polyuria
- Lethargy
- Retinopathy (usually develops alongside): blot haemorrhages, microaneurysms, neovascularisation
INVESTIGATIONS
1st urinalysis: increased early morning ACR : urineary albumin of 30 to 300 mg/d or a random urine albumin-tocreatinine ratio (ACR) between 2 and 20 mg/mmol = microalbuminuria
Need urinalysis for urinary ACR annually]
Serum creatinine and eGFR: GFR raised in early disease amd reduced in late disease
Kidney Ultrasound: look for other cuases like stones or cysts or polynephritis
Kidney Biopsy is gold standard;
- Kimmelstiel-Wilson nodules
- Mesangial expansion
- GBM thickening
MANAGEMENT
1) Hypertension: ACEi or ARB ; 2nd line is CCB or thiazide like diuretic
2) Tight glycaemic control
3) Control dyslipidaemia: atorvastatin
4) Lifestyle: Dietary modification: reduce protein and salt intake
5) Lifestyle: Stop smoking
6) Lifestyle: exercise
PROGNOSIS
morbidity and mortality can be avoided or delayed with intensive treatment of hyperglycaemia, hypertension, and dyslipidaemia and with careful attention to diet and avoidance of nephrotoxic agents
COMPLICATIONS
- end stage renal disease
- hyperkalaemia
- cardiovascular events
- PVD
- anaemia
Diabetes Neuropathy
- aetiology: define, pathophysiology, risk factors
- clinical features
- investigations
- management
- prognosis + complication
Peripheral nerve dysfunction and/or autonomic nerve dysfunction in diabetes patients by blockage of vasa nervorum
Chronic hyperglycaemia → glycation of axon proteins → neuropathy
can lead to: Diabetic foot problems and ulceration (leading cause of diabetes related hospital admissions and non-traumatic amputation). Diabetic foot ulcers usually occur over pressure points like plantar surface of metatarsal head and plantar surface of hallux. Painless with normal ABPI, give cushioned shoes to reduce callous formation
RF:
- poorly controlled hyperglycaemia
- older age (>70yrs old)
- prolonged duration of diabetes (>10yrs)
- tall stature
- hypertension
- dyslipidaemia
CLINICAL FEATURES
Peripheral neuropathy:
- Peripheral pain- burning/sticking/aching- often worse at night
- Loss of peripheral sensation- glove and stocking distribution
- Peripheral dyaesthesia- burning sensation in feet
- Reduced/absent ankle reflexes
- Peripheral painless injuries occurring at pressure points
Mononeuropathy:
Sudden motor loss e.g. wrist drop, foot drop, 3rd nerve palsy (down and out eye)
Autonomic symptoms:
- Resting tachycardia
- Urinary frequency/urgency/nocturia/incontinence/hesitancy/weak stream/retention
- Erectile dysfunction
- Constipation
- Difficulty swallowing
- Postural hypotension
- Gastroparesis- give Metoclopramide (pro kinetic that improves gastric emptying)
autonomic NS neuropathy causes Impaired hypoglycaemia awareness
INVESTIGATIONS:
Sensation, use 10g monofilament, can also use tuning fork (decreased vibration sense) and pinprick
Bloods- fasting blood glucose and HbA1c
MANAGEMENT
If painless; optimise glucose control
If painful:
gabapentin or pregabalin and/or duloxetine (also with glucose control)
2nd line add or replace with amytriptyline
COMPLICATIONS
- foot wounds/ulcers (arterial, venous or neuropathic)
- wound infection/gangrene
- amputation
- silent MI
- depression
- death
PROGNOSIS
depends on how well diabetes is managed. Improvement in blood glucose control may slow the progression of neuropathy, but recovery may be very slow
What patients is amytriptyline contraindicated in
BPH as can cause urinary retention
Hypoglycaemia
- aetiology: define, pathophysiology, risk factors
- clinical features
- investigations
- management
- prognosis + complication
blood glucose falls below the normal fasting glucose range, generally <3.3 mmol/L
Whipples Triad; (low glucose, symptoms, glucose makes better)
- low blood glucose concentration
- hypoglycaemic symptoms
- resolution of symptoms after raising blood glucose concentration to normal
Risk Factors:
Diabetic patients: fasting/missing meals, insulin or sulphonurea use
Drugs: Sulfonylureas and insulin, SGLT2, DPP4
Hormone Deficiency: Hypopituitarism, Adrenal insufficiency- Addisons
Other- liver failure, sepsis, Insulinoma (tumour in pancreas secretes insulin, if administer exogenous insulin C peptide doesnt fall aka keeps secreting insulin)
CLINICAL FEATURES
Increased sympathetic activity: sweating, anxiety, tachycardia, tremor, palpitations, pallor
Increased parasympathetic activity: hunger, nausea, vomiting, paraesthesia
Neuroglycopenic symptoms: confusion, seizures, agitation
INVESTIGATIONS
Bloods:
- glucose: less than 3.3 cause autonomic symptoms, less than 2.8 cause neuroglycopenic symptoms
- insulin: insuloma
- C peptide: if elevated suggests insulinoma, if low suggests exogenous insulin
- cortisol: adrenal insufficiency
Check blood glucose in any confusiond patient with neurological symptoms
MANAGEMENT
Supportive care to correct glucose:
if conscious and can swallow: oral glucose 15-20g (liquid, gel or tablet) and fast acting carbs (glucose tablet, sweets, juice)
if unconscious: IM Glucagon and IV Dextrose (20% glucose).
if impaired GCS: IV glucose
If insuloma: surgical excision
If IGF-II secreting tumour: surgical excision + chemo/radio
COMPLICATIONS
- Seizure
- Coma